PRINCETON, N.J. and SUZHOU, China, April 9, 2026 -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that preclinical research results from two of its internally developed pipeline assets have been selected for poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held in San Diego from April 17 to 22, 2026 (local time).

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

The abstracts are detailed as follows:

Abstract Title: Characterization of osemitamab in pancreatic cancer models and patients

Session Title: Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 1

Session Time: 4/20/2026 9:00:00 AM-4/20/2026 12:00:00 PM

Location: Poster Section 48

Poster Board Number: 21

Presentation Number: 2645

Abstract Title: Preclinical characterization of novel LIV1 antibody drug conjugates

Session Title: Antibody-Drug Conjugates and Linker Engineering 3

Session Time: 4/21/2026 9:00:00 AM- 4/21/2026 12:00:00 PM

Location: Poster Section 12

Poster Board Number: 19

Presentation Number: 4441

About Transcenta Therapeutics

Transcenta (HKEX: 06628) is a global clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in China, U.S. and Europe. Transcenta is developing a diverse pipeline of more than a dozen novel biologic therapies for oncology and selected non-oncology indications including bone and kidney disorders.

For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. For inquiries regarding Business Development opportunities, please contact us at bd@transcenta.com